Cargando…

Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA(1c), Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy

OBJECTIVE: To examine the safety and efficacy of dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, added on to pioglitazone in type 2 diabetes inadequately controlled on pioglitazone. RESEARCH DESIGN AND METHODS: Treatment-naive patients or those receiving metformin, sulfonylurea, or thiazo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rosenstock, Julio, Vico, Marisa, Wei, Li, Salsali, Afshin, List, James F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2012
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3379599/ https://www.ncbi.nlm.nih.gov/pubmed/22446170 http://dx.doi.org/10.2337/dc11-1693

Ejemplares similares

Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise: A randomized, double-blind, placebo-controlled, phase 3 trial
por: Ferrannini, Ele, et al.
Publicado: (2010)

Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin
por: Rosenstock, Julio, et al.
Publicado: (2018)

Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin
por: Ouchi, Motoshi, et al.
Publicado: (2018)

SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice
por: Ali, Amar, et al.
Publicado: (2019)

HbA(1c) and Risk of Severe Hypoglycemia in Type 2 Diabetes: The Diabetes and Aging Study
por: Lipska, Kasia J., et al.
Publicado: (2013)

Correction to: SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice
por: Ali, Amar, et al.
Publicado: (2019)

Glycated Albumin Correlates With Time-in-Range Better Than HbA(1c) or Fructosamine
por: Desouza, Cyrus V, et al.
Publicado: (2023)

Standardization of the HbA(2) Assay
por: Paleari, Renata, et al.
Publicado: (2018)

Measurement of HbA(1c) and HbA(2) by Capillarys 2 Flex Piercing HbA(1c) programme for simultaneous management of diabetes and screening for thalassemia
por: Ke, Peifeng, et al.
Publicado: (2017)

Greater Dose-Ranging Effects on A1C Levels Than on Glucosuria With LX4211, a Dual Inhibitor of SGLT1 and SGLT2, in Patients With Type 2 Diabetes on Metformin Monotherapy
por: Rosenstock, Julio, et al.
Publicado: (2015)

Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes
por: Bailey, Clifford J., et al.
Publicado: (2019)

Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin
por: Schwartz, Stanley S
Publicado: (2010)

Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury
por: Chang, Yoon-Kyung, et al.
Publicado: (2016)

Effects of the SGLT‐2 inhibitor dapagliflozin on glomerular and tubular injury markers
por: Dekkers, Claire C. J., et al.
Publicado: (2018)

Therapeutic effect and rebound evaluation of dapagliflozin on glycated hemoglobin (HbA1c) in type 1 diabetes mellitus patients
por: Wang, Dong-Dong, et al.
Publicado: (2023)

Comparison of the effect of Dapagliflozin and Pioglitazone on the risk of osteoporosis in postmenopausal women with Type-2 diabetes
por: Son, Osman
Publicado: (2023)

Association of long-term visit-to-visit variability of HbA1c and fasting glycemia with hypoglycemia in type 2 diabetes mellitus
por: Long, Chen, et al.
Publicado: (2022)

Correction: Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury
por: Chang, Yoon-Kyung, et al.
Publicado: (2016)

Different levels of hypoglycemia in patients with type 2 diabetes, their achieved mean HbA1c vs. all-cause and cardiovascular mortality
por: Ooi, Seng-Wei, et al.
Publicado: (2023)

Low HbA2 Level in β-Thalassemia Trait
por: ÖZSOYLU, Şinasi
Publicado: (2013)

Engineering of the endogenous HBD promoter increases HbA2
por: Boontanrart, Mandy Y, et al.
Publicado: (2023)

A systematic review and mixed-treatment comparison of dapagliflozin with existing anti-diabetes treatments for those with type 2 diabetes mellitus inadequately controlled by sulfonylurea monotherapy
por: Orme, Michelle, et al.
Publicado: (2014)

Differential Thermal Stability and Oxidative Vulnerability of the Hemoglobin Variants, HbA(2) and HbE
por: Chakrabarti, Abhijit, et al.
Publicado: (2013)

Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with Metformin
por: Kim, Jong Ho, et al.
Publicado: (2016)

Model‐based characterization of the relationship between dapagliflozin systemic exposure and HbA1c response in patients with type 1 diabetes mellitus
por: Parkinson, Joanna, et al.
Publicado: (2019)

Comparing Effectiveness and Safety of SGLT2 Inhibitors vs DPP-4 Inhibitors in Patients With Type 2 Diabetes and Varying Baseline HbA(1c) Levels
por: D’Andrea, Elvira, et al.
Publicado: (2023)

Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial
por: Bailey, Clifford J, et al.
Publicado: (2013)

Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus
por: Whaley, Jean M, et al.
Publicado: (2012)

A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation
por: Ott, Christian, et al.
Publicado: (2017)

What to do with diabetes therapies when HbA1c lowering is inadequate: add, switch, or continue? A MASTERMIND study
por: McGovern, Andrew P., et al.
Publicado: (2019)

Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure
por: Tye, Sok Cin, et al.
Publicado: (2022)

Changes in HbA1c, body weight, and systolic blood pressure in type 2 diabetes patients initiating dapagliflozin therapy: a primary care database study
por: Scheerer, Markus F, et al.
Publicado: (2016)

Correction: Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial
por: Bailey, Clifford J, et al.
Publicado: (2013)

The Risk of Bladder Cancer in Type 2 Diabetes Mellitus with Combination Therapy of SGLT-2 Inhibitors and Pioglitazone
por: Li, Yan-Rong, et al.
Publicado: (2021)

HbA(1c): The lower the better?
por: Araki, Eiichi, et al.
Publicado: (2011)

Visit-to-visit HbA1c variability is inversely related to baroreflex sensitivity independently of HbA1c value in type 2 diabetes
por: Matsutani, Daisuke, et al.
Publicado: (2018)

HbA(1c) After a Short Period of Monotherapy With Metformin Identifies Durable Glycemic Control Among Adolescents With Type 2 Diabetes
por: Zeitler, Phil, et al.
Publicado: (2015)

Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus
por: Fioretto, Paola, et al.
Publicado: (2015)

The Effect of SGLT2 Inhibitor Dapagliflozin on Serum Levels of Apelin in T2DM Patients with Heart Failure
por: Berezin, Alexander A., et al.
Publicado: (2022)

Effects of SGLT2 inhibitor dapagliflozin in patients with type 2 diabetes on skeletal muscle cellular metabolism
por: op den Kamp, Yvo J.M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5nqp5o9b66ibvu9o1dfvkv6a67